218 related articles for article (PubMed ID: 37975846)
21. Design of multifunctional peptide collaborated and docetaxel loaded lipid nanoparticles for antiglioma therapy.
Kadari A; Pooja D; Gora RH; Gudem S; Kolapalli VRM; Kulhari H; Sistla R
Eur J Pharm Biopharm; 2018 Nov; 132():168-179. PubMed ID: 30244167
[TBL] [Abstract][Full Text] [Related]
22. Potential of Nanocarrier-Associated Approaches for Better Therapeutic Intervention in the Management of Glioblastoma.
Vikram ; Kumar S; Ali J; Baboota S
Assay Drug Dev Technol; 2024; 22(2):73-85. PubMed ID: 38193798
[No Abstract] [Full Text] [Related]
23. Breaching barriers in glioblastoma. Part II: Targeted drug delivery and lipid nanoparticles.
Miranda A; Blanco-Prieto MJ; Sousa J; Pais A; Vitorino C
Int J Pharm; 2017 Oct; 531(1):389-410. PubMed ID: 28801108
[TBL] [Abstract][Full Text] [Related]
24. Brain-targeted Nano-architectures for Efficient Drug Delivery and Sensitization in Glioblastoma.
Ravuluri JAV; Rao V; Kumar G; Manandhar S; Cheruku SP; Bisht P; Chamallmudi MR; Nandakumar K; Kumar L; Kumar N
Curr Pharm Des; 2023; 29(22):1775-1790. PubMed ID: 37403389
[TBL] [Abstract][Full Text] [Related]
25. Glioblastoma chemotherapeutic agents used in the clinical setting and in clinical trials: Nanomedicine approaches to improve their efficacy.
Aparicio-Blanco J; Sanz-Arriazu L; Lorenzoni R; Blanco-Prieto MJ
Int J Pharm; 2020 May; 581():119283. PubMed ID: 32240807
[TBL] [Abstract][Full Text] [Related]
26. Lipid-based nanoparticles to address the limitations of GBM therapy by overcoming the blood-brain barrier, targeting glioblastoma stem cells, and counteracting the immunosuppressive tumor microenvironment.
Zhao C; Zhu X; Tan J; Mei C; Cai X; Kong F
Biomed Pharmacother; 2024 Feb; 171():116113. PubMed ID: 38181717
[TBL] [Abstract][Full Text] [Related]
27. Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment.
Ganipineni LP; Danhier F; Préat V
J Control Release; 2018 Jul; 281():42-57. PubMed ID: 29753958
[TBL] [Abstract][Full Text] [Related]
28. A potential non-invasive glioblastoma treatment: Nose-to-brain delivery of farnesylthiosalicylic acid incorporated hybrid nanoparticles.
Sekerdag E; Lüle S; Bozdağ Pehlivan S; Öztürk N; Kara A; Kaffashi A; Vural I; Işıkay I; Yavuz B; Oguz KK; Söylemezoğlu F; Gürsoy-Özdemir Y; Mut M
J Control Release; 2017 Sep; 261():187-198. PubMed ID: 28684169
[TBL] [Abstract][Full Text] [Related]
29. Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain.
Agarwal S; Sane R; Oberoi R; Ohlfest JR; Elmquist WF
Expert Rev Mol Med; 2011 May; 13():e17. PubMed ID: 21676290
[TBL] [Abstract][Full Text] [Related]
30. Targeted Vascular Drug Delivery in Cerebral Cancer.
Humle N; Johnsen KB; Arendt GA; Nielsen RP; Moos T; Thomsen LB
Curr Pharm Des; 2016; 22(35):5487-5504. PubMed ID: 27464719
[TBL] [Abstract][Full Text] [Related]
31. Surface Engineered Dendrimers: A Potential Nanocarrier for the Effective Management of Glioblastoma Multiforme.
Sahoo RK; Gupta T; Batheja S; Goyal AK; Gupta U
Curr Drug Metab; 2022; 23(9):708-722. PubMed ID: 35713127
[TBL] [Abstract][Full Text] [Related]
32. Lipid-Based Nanocarriers in the Treatment of Glioblastoma Multiforme (GBM): Challenges and Opportunities.
Gupta T; Sahoo RK; Singh H; Katke S; Chaurasiya A; Gupta U
AAPS PharmSciTech; 2023 Apr; 24(4):102. PubMed ID: 37041350
[TBL] [Abstract][Full Text] [Related]
33. Delivery across the blood-brain barrier: nanomedicine for glioblastoma multiforme.
Jena L; McErlean E; McCarthy H
Drug Deliv Transl Res; 2020 Apr; 10(2):304-318. PubMed ID: 31728942
[TBL] [Abstract][Full Text] [Related]
34. Drug Delivery and Targeting to the Brain Through Nasal Route: Mechanisms, Applications and Challenges.
Kashyap K; Shukla R
Curr Drug Deliv; 2019; 16(10):887-901. PubMed ID: 31660815
[TBL] [Abstract][Full Text] [Related]
35. Amphetamine decorated cationic lipid nanoparticles cross the blood-brain barrier: therapeutic promise for combating glioblastoma.
Saha S; Yakati V; Shankar G; Jaggarapu MMCS; Moku G; Madhusudana K; Banerjee R; Ramkrishna S; Srinivas R; Chaudhuri A
J Mater Chem B; 2020 May; 8(19):4318-4330. PubMed ID: 32330214
[TBL] [Abstract][Full Text] [Related]
36. Enhancement of Therapies for Glioblastoma (GBM) Using Nanoparticle-based Delivery Systems.
Wiwatchaitawee K; Quarterman JC; Geary SM; Salem AK
AAPS PharmSciTech; 2021 Feb; 22(2):71. PubMed ID: 33575970
[TBL] [Abstract][Full Text] [Related]
37. Design of Biopolymer-Based Interstitial Therapies for the Treatment of Glioblastoma.
Pena ES; Graham-Gurysh EG; Bachelder EM; Ainslie KM
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884965
[TBL] [Abstract][Full Text] [Related]
38. Molecular Mechanisms of Drug Resistance in Glioblastoma.
Dymova MA; Kuligina EV; Richter VA
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34203727
[TBL] [Abstract][Full Text] [Related]
39. Novel delivery strategies for glioblastoma.
Zhou J; Atsina KB; Himes BT; Strohbehn GW; Saltzman WM
Cancer J; 2012; 18(1):89-99. PubMed ID: 22290262
[TBL] [Abstract][Full Text] [Related]
40. Stimuli-Responsive Multifunctional Nanomedicine for Enhanced Glioblastoma Chemotherapy Augments Multistage Blood-to-Brain Trafficking and Tumor Targeting.
Martins C; Araújo M; Malfanti A; Pacheco C; Smith SJ; Ucakar B; Rahman R; Aylott JW; Préat V; Sarmento B
Small; 2023 Jun; 19(22):e2300029. PubMed ID: 36852650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
